Obstructive Sleep Apnea Market Forecast 2034: Rising Demand, Novel Therapies, and Commercial Potential by 2034 - DelveInsight

DelveInsight's "Obstructive Sleep Apnea Market Insights, Epidemiology, and Market Forecast-2034" report provides a comprehensive understanding of obstructive sleep apnea (OSA), including historical and forecasted epidemiology, as well as market trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

Get a Free Sample for the Obstructive Sleep Apnea Market Report:
https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Key Facts of the Obstructive Sleep Apnea Market Report

• The Obstructive Sleep Apnea market is projected to expand at a significant CAGR during the forecast period (2024-2034), driven by increasing disease awareness, improved diagnosis rates, and the anticipated launch of innovative therapies.
• In 2023, the total diagnosed prevalent population of Obstructive Sleep Apnea across the 7MM was approximately 25.67 million, and this patient pool is expected to increase steadily through 2034.
• DelveInsight estimates indicate that in 2023, Japan recorded approximately 3.19 million diagnosed male cases and 1.82 million diagnosed female cases, highlighting the higher disease burden among males.
• The Obstructive Sleep Apnea market was valued at nearly USD 359 million across the 7MM in 2023 and is projected to grow at a CAGR of approximately 17% through 2034, supported by the launch of emerging therapies.
• In December 2024, Eli Lilly and Company received US FDA approval for Zepbound (tirzepatide) as the first prescription medicine indicated for adults with moderate-to-severe obstructive sleep apnea and obesity.
• In June 2024, Eli Lilly reported positive results from the SURMOUNT-OSA Phase III clinical trials, demonstrating that tirzepatide significantly reduced disease severity in adults with obesity and moderate-to-severe obstructive sleep apnea. The company subsequently submitted the therapy to the US FDA and initiated regulatory filings in additional global markets.
• In April 2024, Incannex Healthcare advanced IHL-42X into Phase II/III clinical development for obstructive sleep apnea, aiming to provide a non-invasive pharmacological alternative for patients who struggle with positive airway pressure (PAP) therapy adherence.
• In May 2024, Incannex Healthcare announced the initiation of patient dosing in its Phase II/III clinical trial evaluating the safety and efficacy of IHL-42X in patients with obstructive sleep apnea.
• Eli Lilly continues strengthening its obstructive sleep apnea pipeline with Retatrutide (LY3437943), a GIP, GLP-1, and glucagon receptor triagonist, alongside Tirzepatide (LY3298176), expanding its leadership in obesity-associated sleep disorders.
• In 2023, the United States accounted for approximately 54% of diagnosed prevalent obstructive sleep apnea cases across the 7MM, representing nearly 13.76 million patients.
• Japan represented nearly 20% of the diagnosed prevalent obstructive sleep apnea population across the 7MM in 2023.
• Adults aged 65 years and older represented the largest patient population, accounting for approximately 8.87 million diagnosed cases across the 7MM in 2023.
• In the EU4 and the UK, approximately 2.46 million mild, 1.78 million moderate, and 2.66 million severe obstructive sleep apnea cases were reported in 2023.
• In the United States, approximately 4.28 million mild, 3.28 million moderate, and 6.21 million severe obstructive sleep apnea cases were reported in 2023.
• Current marketed therapies primarily address excessive daytime sleepiness associated with obstructive sleep apnea, while several disease-modifying therapies are advancing through late-stage clinical development.
• Key Obstructive Sleep Apnea Companies include Apnimed, Eli Lilly and Company, Nyxoah Inc., ICUREsearch, Eisai Inc., Purdue Pharma LP, Desitin Arzneimittel GmbH, Berendo Scientific LLC, Sumitomo Pharma America Inc., and Apnex Medical Inc.
• Key Obstructive Sleep Apnea therapies include Zepbound (tirzepatide), Retatrutide (LY3437943), AD109, SUNOSI (solriamfetol), OZAWADE (pitolisant), and IHL-42X, among others.
• The Obstructive Sleep Apnea market is expected to witness substantial growth owing to the increasing disease burden, improved awareness, expanding diagnosis rates, and the anticipated introduction of innovative pharmacological therapies designed to improve patient adherence and long-term disease management.

Obstructive Sleep Apnea Overview

Obstructive Sleep Apnea (OSA) is a chronic sleep-related breathing disorder characterized by repeated episodes of complete or partial upper airway obstruction during sleep. These episodes result in intermittent reductions or complete pauses in airflow, leading to fragmented sleep, oxygen desaturation, excessive daytime sleepiness, impaired cognitive function, and an increased risk of cardiovascular and metabolic complications. Current treatment options include continuous positive airway pressure (CPAP), oral appliances, lifestyle modifications, weight management, and surgical interventions. Despite these approaches, long-term adherence remains a significant challenge, creating opportunities for innovative pharmacological therapies aimed at improving patient outcomes and treatment compliance.

To know more about the Obstructive Sleep Apnea market outlook, epidemiology trends, treatment landscape, and drug uptake, visit the Obstructive Sleep Apnea Market Report:
https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Obstructive Sleep Apnea Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends of Obstructive Sleep Apnea (OSA) across the seven major markets (7MM) from 2020 to 2034. It examines the diagnosed patient population and future disease trends by analyzing published studies and expert perspectives. The section also offers a detailed assessment of the diagnosed prevalent population segmented by age, gender, and disease severity.

Obstructive Sleep Apnea Epidemiology Segmentation

• Total Diagnosed Prevalent Cases of Obstructive Sleep Apnea
• Gender-specific Diagnosed Prevalent Cases of Obstructive Sleep Apnea
• Age-specific Diagnosed Prevalent Cases of Obstructive Sleep Apnea
• Severity-specific Diagnosed Prevalent Cases of Obstructive Sleep Apnea

Download the report to understand which factors are driving Obstructive Sleep Apnea epidemiology trends @ Obstructive Sleep Apnea Epidemiology Forecast:
https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Obstructive Sleep Apnea Drugs Uptake and Pipeline Development Activities

The drugs uptake section evaluates the adoption rate of recently launched and upcoming therapies expected to enter the Obstructive Sleep Apnea market during the forecast period. It analyzes therapy uptake, patient adoption, market penetration, and expected sales performance of individual therapies.

The therapeutics assessment also highlights drugs expected to achieve rapid uptake based on clinical efficacy, safety profile, route of administration, patient convenience, and physician preference. Additionally, the report compares therapies according to their projected market share.

The report also provides a comprehensive overview of the Obstructive Sleep Apnea pipeline, highlighting therapeutic candidates in Phase II and Phase III development. It further analyzes recent clinical progress, regulatory milestones, collaborations, mergers and acquisitions, licensing agreements, patent activity, and other strategic developments shaping the future treatment landscape.

Obstructive Sleep Apnea Therapies and Key Companies

• Zepbound (tirzepatide): Eli Lilly and Company
• Retatrutide (LY3437943): Eli Lilly and Company
• AD109: Apnimed
• IHL-42X: Incannex Healthcare
• OZAWADE (pitolisant): Bioprojet Pharma/Aculys Pharma
• SUNOSI (solriamfetol): Jazz Pharmaceuticals/Axsome Therapeutics/Pharmanovia
• Additional pipeline therapies from Nyxoah Inc., ICUREsearch, Eisai Inc., Purdue Pharma LP, Desitin Arzneimittel GmbH, Berendo Scientific LLC, Sumitomo Pharma America Inc., Apnex Medical Inc., and others.

Discover more about therapies expected to capture significant Obstructive Sleep Apnea market share @ Obstructive Sleep Apnea Treatment Market:
https://www.delveinsight.com/sample-request/obstructive-sleep-apnea-osa-market?utm_source=openpr&utm_medium=pr&utm_campaign=kkpr

Obstructive Sleep Apnea Market Drivers

• Increasing prevalence of Obstructive Sleep Apnea across the 7MM.
• Rising awareness and improved diagnosis through advanced sleep testing technologies.
• Growing development of innovative pharmacological therapies beyond PAP devices.
• Strong late-stage pipeline, including tirzepatide, retatrutide, AD109, and IHL-42X.
• Increasing regulatory support and continued investment in sleep medicine research.

Obstructive Sleep Apnea Market Barriers

• High treatment costs associated with advanced therapies.
• Poor long-term adherence to CPAP and other PAP devices.
• Significant diagnostic gaps and underdiagnosis in many patient populations.
• Limited availability of approved disease-modifying pharmacological treatments.
• Challenges related to reimbursement and patient access across different healthcare systems.

Scope of the Obstructive Sleep Apnea Market Report

• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU4 (Germany, France, Italy, Spain), the United Kingdom, and Japan]
• Key Obstructive Sleep Apnea Companies: Apnimed, Eli Lilly and Company, Nyxoah Inc., ICUREsearch, Eisai Inc., Purdue Pharma LP, Desitin Arzneimittel GmbH, Berendo Scientific LLC, Sumitomo Pharma America Inc., Apnex Medical Inc., and others.
• Key Obstructive Sleep Apnea Therapies: Zepbound (tirzepatide), Retatrutide (LY3437943), AD109, IHL-42X, SUNOSI (solriamfetol), OZAWADE (pitolisant), and others.
• Obstructive Sleep Apnea Therapeutic Assessment: Current marketed therapies and emerging pipeline therapies.
• Obstructive Sleep Apnea Market Dynamics: Market drivers and market barriers.
• Competitive Intelligence Analysis: SWOT Analysis, Conjoint Analysis, reimbursement analysis, market access assessment, and competitive landscape evaluation.
• Obstructive Sleep Apnea Unmet Needs, KOL Views, Analyst Perspectives, and Market Access & Reimbursement Analysis.

Table of Contents

• Key Insights
• Report Introduction
• Obstructive Sleep Apnea (OSA) Market Overview at a Glance
• Epidemiology and Market Methodology of OSA
• Executive Summary of Obstructive Sleep Apnea
• Key Events
• Disease Background and Overview of OSA
• Epidemiology and Patient Population
• Patient Journey
• Marketed Drugs
• Emerging Therapies
• OSA Market Analysis
• KOL Views
• SWOT Analysis
• Unmet Needs
• Market Access and Reimbursement
• Appendix
• DelveInsight Capabilities
• Disclaimer

Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: kkumar@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.